載入中
uniQure N.V. develops treatments for patients suffering from rare and other devastating diseases in the United States. The company offers HEMGENIX that allows people living with hemophilia B to produce factor IX, which can lower the risk of bleeding. Its lead product candidate is AMT-130, a gene therapy candidate, which is in phase I/II clinical study for the treatment of Huntington’s disease. The company also develops AMT-260, which is in phase I/IIa clinical trial for the treatment of mesial temporal lobe epilepsy; AMT-162, which is in phase I/IIa clinical trial to treat superoxide dismutase enzyme-amyotrophic lateral sclerosis; and AMT-191, an investigational gene therapy candidate which is in phase I/IIa clinical trial for the treatment of fabry disease. It has a licensing agreement with Apic Bio to develop, manufacture, and commercialize intrathecally administered investigational gene therapy for ALS caused by mutations in SOD-1; and development and commercial supply agreement with CLS Bhering. uniQure N.V. was founded in 1998 and is headquartered in Amsterdam, the Netherlands.
前收盤價
US$22.59
+US$0.05 · +0.22%
盤中時間採用ET。市場資料可能有所延遲。
uniQure N.V. develops treatments for patients suffering from rare and other devastating diseases in the United States. The company offers HEMGENIX that allows people living with hemophilia B to produce factor IX, which can lower the risk of bleeding. Its lead product candidate is AMT-130, a gene therapy candidate, which is in phase I/II clinical study for the treatment of Huntington’s disease. The company also develops AMT-260, which is in phase I/IIa clinical trial for the treatment of mesial temporal lobe epilepsy; AMT-162, which is in phase I/IIa clinical trial to treat superoxide dismutase enzyme-amyotrophic lateral sclerosis; and AMT-191, an investigational gene therapy candidate which is in phase I/IIa clinical trial for the treatment of fabry disease. It has a licensing agreement with Apic Bio to develop, manufacture, and commercialize intrathecally administered investigational gene therapy for ALS caused by mutations in SOD-1; and development and commercial supply agreement with CLS Bhering. uniQure N.V. was founded in 1998 and is headquartered in Amsterdam, the Netherlands.
日內區間
目前US$22.59
52週區間
目前US$22.59
盤中時間採用ET。市場資料可能有所延遲。
uniQure N.V. develops treatments for patients suffering from rare and other devastating diseases in the United States. The company offers HEMGENIX that allows people living with hemophilia B to produce factor IX, which can lower the risk of bleeding. Its lead product candidate is AMT-130, a gene therapy candidate, which is in phase I/II clinical study for the treatment of Huntington’s disease. The company also develops AMT-260, which is in phase I/IIa clinical trial for the treatment of mesial temporal lobe epilepsy; AMT-162, which is in phase I/IIa clinical trial to treat superoxide dismutase enzyme-amyotrophic lateral sclerosis; and AMT-191, an investigational gene therapy candidate which is in phase I/IIa clinical trial for the treatment of fabry disease. It has a licensing agreement with Apic Bio to develop, manufacture, and commercialize intrathecally administered investigational gene therapy for ALS caused by mutations in SOD-1; and development and commercial supply agreement with CLS Bhering. uniQure N.V. was founded in 1998 and is headquartered in Amsterdam, the Netherlands.
日內區間
目前US$22.59
52週區間
目前US$22.59
近期已公布業績
近期已公布業績
第三方分析師預期可能變動，並非 GoAI 建議。
報告持有此股票曝險的交易所交易基金。
State Street SPDR S&P Biotech ETFXBI4640.93萬0.47%98.74億 USD0.35%US$153.77+3.00%
Vanguard Extended Market ETFVXF3847.48萬0.04%954億 USD0.05%US$235+0.80%
iShares Biotechnology ETFIBB1126.02萬0.11%108.2億 USD0.44%US$206.49+3.00%
Schwab U.S. Small-Cap ETFSCHA827.39萬0.04%218.24億 USD0.03%US$32.79+0.40%
Vanguard Health Care ETFVHT766.19萬0.03%220億 USD0.09%US$319.01+1.64%
Invesco Dorsey Wright Healthcare Momentum ETFPTH298.62萬1.04%2.87億 USD0.74%US$58.757+2.42%
Direxion Daily S&P Biotech Bull 3X SharesLABU218.55萬0.37%5.97億 USD0.96%US$243.09+9.01%
iShares Core S&P Total U.S. Stock Market ETFITOT201.38萬0.00%980.88億 USD0.03%US$169.66+0.64%State Street SPDR S&P Biotech ETFXBIVanguard Extended Market ETFVXFiShares Biotechnology ETFIBBSchwab U.S. Small-Cap ETFSCHAVanguard Health Care ETFVHTInvesco Dorsey Wright Healthcare Momentum ETFPTHDirexion Daily S&P Biotech Bull 3X SharesLABUiShares Core S&P Total U.S. Stock Market ETFITOTAI 生成內容及延遲市場資料僅供資訊與教育用途，不構成投資建議。
